Congress Materials – Psych Congress Elevate (Psych Elevate 2026)
2026 Psych Congress Elevate | Jun 3-6 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy of Lumateperone 42 mg for the Treatment of Adults With Schizophrenia and Clinically Relevant Depressive Symptoms: Results of a Post Hoc Pooled Analysis
Christoph U. Correll, Karen Johnston, Ibrahim Turkoz, Monica Doring, Preeti Jalli, Kristin R Dorsey, Josh Hamilton
This document will be available after June 4th 2026
Efficacy of Lumateperone 42 mg for the Treatment of Major Depressive Disorder: Analysis of Demographic and Clinical Subgroups in a Phase 3 Randomized Placebo-Controlled Trial
Suresh Durgam; Willie R. Earley; Niko Wagner; Hassan Lakkis; Roger S. McIntyre Maurizio Fava
This document will be available after June 4th 2026
First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
Willie R. Earley; Suresh Durgam; Susan G. Kozauer; Collin Merrill; Changzheng Chen; Andrew J. Cutler; Stephen M. Stahl
This document will be available after June 4th 2026
Incidence of Cardiometabolic Outcomes Among Patients With Major Depressive Disorder Treated With Antidepressants and/or Adjunctive Antipsychotics: A Real-World Evidence Study
Nilanjana Dwibedi, Zhiheng Zhang, Hrishikesh Kale, Kathryn Krupsky, M. Janelle Cambron-Mellott, Kyla Finlayson, Manish Jha, Joshua Hamilton
This document will be available after June 4th 2026
Long-Term Efficacy of Lumateperone 42 mg for the Treatment of Adults with Schizophrenia and Clinically Relevant Depressive Symptoms: A Post Hoc Analysis of a 1-Year Open-Label Study
Christoph U. Correll, Karen Johnston, Ibrahim Turkoz, Monica Doring, Preeti Jalli, Kristin R Dorsey, Josh Hamilton
This document will be available after June 4th 2026
Rapid and Sustained Remission with Esketamine Nasal Spray in Adult Patients with Treatment-Resistant Depression: Overview of Remission Rates from Six Clinical Trials
Rakesh Jain, D.J. Fu, Ibrahim Turkoz, Mai Himeden, Lisa Lim, Oliver Lopena, Ronaldo Naranjo Jr., Lilianna Ly, Alexis Davis, Allen Wu, Kristian Dambrino
This document will be available after June 4th 2026
Real-world Prescribing Patterns of Esketamine Monotherapy vs Adjunctive Therapy in Routine Psychiatric Care
Emily Shish, Jamie Lo, Dejan Milentijevic, Brahim Bookhart, Jimmy Qian
This document will be available after June 4th 2026
Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials
Suresh Durgam; Willie R. Earley; Changzheng Chen; Betsy Yuan; Michael E. Thase
This document will be available after June 4th 2026
Response and Remission Following Esketamine Nasal Spray Initiation in Treatment-Resistant Depression: Real-World Evidence from a Multi-Site Practice
Tobias Marton, Dejan Milentijevic, Yuxian Du, Maryia Zhdanava, Arthur Voegel, Anabelle Tardif-Samson, Loren Ormenaj, Dominic Pilon, Brahim Bookhart
This document will be available after June 4th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.